Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.
Iacovino ML, Miceli CC, De Felice M, Barone B, Pompella L, Chiancone F, Di Zazzo E, Tirino G, Della Corte CM, Imbimbo C, De Vita F, Crocetto F. Iacovino ML, et al. Among authors: de felice m, de vita f. Int J Mol Sci. 2022 Jan 20;23(3):1133. doi: 10.3390/ijms23031133. Int J Mol Sci. 2022. PMID: 35163064 Free PMC article. Review.
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F. Morgillo F, et al. Among authors: de vita f, de palma r. Clin Cancer Res. 2013 Jul 1;19(13):3508-19. doi: 10.1158/1078-0432.CCR-12-2777. Epub 2013 May 21. Clin Cancer Res. 2013. PMID: 23695170
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F. Della Corte CM, et al. Among authors: de vita f. Oncotarget. 2016 Jan 26;7(4):4265-78. doi: 10.18632/oncotarget.6559. Oncotarget. 2016. PMID: 26673006 Free PMC article.
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.
Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F. Fasano M, et al. Among authors: de vita f. Oncol Lett. 2016 Dec;12(6):4505-4509. doi: 10.3892/ol.2016.5279. Epub 2016 Oct 18. Oncol Lett. 2016. PMID: 28105159 Free PMC article.
Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.
Laterza MM, Pompella L, Petrillo A, Tirino G, Pappalardo A, Orditura M, Troiani T, Ciardiello F, Di Martino N, De Vita F. Laterza MM, et al. Among authors: de vita f. Med Oncol. 2017 Oct 17;34(11):186. doi: 10.1007/s12032-017-1046-7. Med Oncol. 2017. PMID: 29043514 Clinical Trial.
Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.
Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F, Orditura M. Morgillo F, et al. Among authors: de vita f. Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100327 Free PMC article.
295 results